

INDUSTRY SYMPOSIUM DURING THE 33RD EUROPEAN CONGRESS ON OBESITY, TAKING PLACE  
12-15 MAY 2026 IN ISTANBUL, TÜRKİYE

# Expanding frontiers in cardiometabolic care with amylin-based therapies

Wednesday 13 May, 13.45-15.15 TRT  
Hall 1, Istanbul Congress Center and online

## Chaired by:

Professor  
Carel le Roux



## Including expert faculty:

Professor  
Gema Frühbeck



Dr Anna Secher,  
Novo Nordisk



Professor  
Kirsi Pietiläinen



Professor  
Matthias Blüher



Professor  
Donna Ryan



13.45-13.50

### Setting the scene: defining the need for amylin

*Carel le Roux (Ireland)*

13.50-14.10

### Like a phoenix from the ashes: reviving amylin biology for clinical impact

*Gema Frühbeck (Spain) and Anna Secher (Denmark)*

14.10-14.30

### CagriSema: from early-phase evidence to REDEFINING obesity care

*Kirsi Pietiläinen (Finland)*

14.30-14.40

### Zenagamtide (amycretin): a new chapter in amylin-based therapies

*Matthias Blüher (Germany)*

14.40-15.00

### Looking ahead: the potential role of amylin-based therapies in obesity care

*Donna Ryan (USA)*

15.00-15.15

### Looking ahead: where do we go next?

*All faculty, facilitated by Carel le Roux (Ireland)*



Lunch will be provided as  
part of the symposium